Celcuity (NASDAQ:CELC) Sets New 12-Month High - Should You Buy?

Key Points

• Celcuity's share price reached a new 52-week high of $81.56 during trading, marking a significant increase from a prior close of $51.96.
• Investment analysts have mixed ratings for Celcuity, with five analysts issuing a "Buy" rating and one a "Sell" rating; the average price target set is $56.50.
• The company reported a quarterly loss of ($1.04) earnings per share, which was below the consensus estimate, highlighting potential concerns over its financial performance.

Celcuity, Inc. (NASDAQ:CELC - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $78.88 and last traded at $81.56, with a volume of 1295740 shares traded. The stock had previously closed at $51.96.

Wall Street Analyst Weigh In

CELC has been the topic of several research analyst reports. Wall Street Zen raised shares of Celcuity from a "sell" rating to a "hold" rating in a research report on Saturday. Needham & Company LLC reissued a "buy" rating and set a $70.00 target price on shares of Celcuity in a research report on Monday. Guggenheim initiated coverage on shares of Celcuity in a research report on Monday, September 22nd. They set a "buy" rating on the stock. Leerink Partners boosted their target price on shares of Celcuity from $28.00 to $60.00 and gave the stock an "outperform" rating in a research report on Monday, July 28th. Finally, Stifel Nicolaus initiated coverage on shares of Celcuity in a research report on Tuesday, July 1st. They set a "buy" rating and a $30.00 target price on the stock. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Celcuity has an average rating of "Moderate Buy" and an average price target of $56.50.

Celcuity Price Performance

The firm's fifty day moving average price is $51.77 and its 200 day moving average price is $27.69. The firm has a market capitalization of $3.08 billion, a PE ratio of -21.22 and a beta of 0.70. The company has a current ratio of 4.58, a quick ratio of 4.58 and a debt-to-equity ratio of 2.24.

Celcuity (NASDAQ:CELC - Get Free Report) last posted its earnings results on Thursday, August 14th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.14). As a group, equities analysts forecast that Celcuity, Inc. will post -2.62 earnings per share for the current year.

Insiders Place Their Bets

In other Celcuity news, Director David Dalvey sold 100,000 shares of the company's stock in a transaction on Monday, July 28th. The shares were sold at an average price of $43.98, for a total transaction of $4,398,000.00. Following the completion of the transaction, the director directly owned 125,000 shares in the company, valued at approximately $5,497,500. This represents a 44.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 15.78% of the company's stock.

Hedge Funds Weigh In On Celcuity

Large investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC raised its position in Celcuity by 1,237.4% during the first quarter. GAMMA Investing LLC now owns 1,324 shares of the company's stock worth $131,000 after acquiring an additional 1,225 shares during the period. Avanza Fonder AB acquired a new stake in shares of Celcuity in the third quarter valued at about $79,000. BNP Paribas Financial Markets raised its position in shares of Celcuity by 78.9% in the second quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company's stock valued at $35,000 after buying an additional 1,167 shares during the last quarter. Tower Research Capital LLC TRC raised its position in shares of Celcuity by 211.2% in the second quarter. Tower Research Capital LLC TRC now owns 5,549 shares of the company's stock valued at $74,000 after buying an additional 3,766 shares during the last quarter. Finally, AlphaQuest LLC raised its position in shares of Celcuity by 176.3% in the second quarter. AlphaQuest LLC now owns 7,087 shares of the company's stock valued at $95,000 after buying an additional 4,522 shares during the last quarter. 63.33% of the stock is currently owned by institutional investors and hedge funds.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.